Repligen (RGEN) Q2 2026: Protein Franchise Soars 50%, Margin Expansion Accelerates Strategic Shift
Repligen’s Q2 saw a sharp acceleration in protein segment growth and margin expansion, validating its innovation and portfolio pivot. Order momentum and robust recurring revenue are driving a guidance raise, even as filtration and capital equipment remain muted near-term. The pending BioLife acquisition signals a deeper commitment to cell therapy, positioning Repligen for multi-year outperformance as market dynamics shift.
Summary
- Protein and Analytics Outperformance: Franchise momentum in proteins and analytics is outpacing market trends and compensating for filtration headwinds.
- Margin Expansion Validates Operational Discipline: Leveraged cost controls and favorable mix are driving margin gains, supporting a guidance raise.
- BioLife Acquisition as Growth Catalyst: The pending deal accelerates Repligen’s cell therapy ambitions and enhances its integrated solutions platform.
Business Overview
Repligen is a bioprocessing technology provider supplying products and solutions to biopharma, contract development and manufacturing organizations (CDMOs), and emerging biotech customers. The company generates revenue through recurring consumables, capital equipment, and services across four major franchises: filtration, chromatography, proteins, and analytics. Its business model relies on innovation-led growth, recurring sales, and selective M&A to expand its portfolio and market reach.
Performance Analysis
Repligen delivered 13% organic revenue growth in Q2, driven by standout performance in proteins (up 50%) and analytics (up 30%+), while filtration remained flat and capital equipment was stable sequentially but up high single digits for the first half. Recurring revenue, particularly from consumables and services, provided a stable base, with emerging biotech and APAC customers leading geographic and customer class growth. Adjusted operating margin expanded by 460 basis points year-over-year, reflecting pricing power, favorable mix, and disciplined cost controls.
Asia-Pacific (APAC) growth was particularly notable at 40%, with China up 60% in the first half, highlighting the effectiveness of Repligen’s regional strategy and OEM partnerships. North America also contributed high-teens growth, while EMEA was down due to tough comps. Gross margin benefited from volume leverage and product mix, with a one-time tariff refund providing a minor boost. Free cash flow conversion remained strong, and the balance sheet is robust with $810 million in cash and equivalents.
- Protein Franchise Acceleration: Broad-based portfolio strength, including custom ligands, growth factors, and PureLight OEM partnerships, fueled 50% growth and a guidance raise for the segment.
- Filtration and Capital Equipment Remain Near-Term Drags: Filtration growth was muted due to expected headwinds from gene therapy and customer-specific delays, but order trends for ATF and equipment signal a 2027 rebound.
- Margin Expansion Outpaces Revenue: Operating and gross margin gains were driven by pricing, mix, and cost discipline, enabling a higher full-year margin outlook despite planned second-half investments.
Repligen’s performance reflects a portfolio shift toward higher-growth, higher-margin segments, and the company is well positioned to capitalize on a recovery in filtration and equipment in 2027.
Executive Commentary
"Our team executed at a high level, driving 12% reported growth, which translated to 13% organic growth and 460 basis points of adjusted operating margin expansion. Reflecting on our strong first half results and with our increased conviction in the full year outlook, we are raising our organic revenue growth and adjusted EPS guidance."
Olivier Loeillot, President and Chief Executive Officer
"Underlying our adjusted operating income margin expansion in the quarter was strong operating leverage achieved with a modest adjusted OPEX growth of 6% on a reported basis and 8% excluding the impact from the Polymem sale and foreign currency. We have remained prudent in our spending and have taken a measured approach to headcount additions in the first half."
Jason Garland, Chief Financial Officer
Strategic Positioning
1. Protein Franchise Reinvention
Repligen’s protein business, spanning custom ligands, growth factors, and OEM partnerships, is now a primary growth engine after a strategic pivot post-OEM deal losses. Portfolio innovation, such as Avitide and PureLight partnerships, is enabling outperformance versus market growth rates, with management confident in the durability of these drivers as adoption broadens beyond new modalities.
2. Analytics and Lifecycle Management
The analytics segment is benefiting from both consumables and capital equipment, driven by life cycle management strategies such as the solo VPA plus upgrade cycle. Repligen’s focus on continuous innovation and frictionless upgrades is increasing customer stickiness and supporting recurring revenue growth.
3. Filtration and Capital Equipment Setup for 2027
While filtration and capital equipment are facing temporary headwinds from customer inventory and site readiness, order book strength and RFP wins are building backlog for 2027. Management expects normalization in Q4 and a strong rebound in ATF and equipment as new programs ramp and onshoring trends accelerate.
4. BioLife Acquisition Fast-Tracks Cell Therapy Strategy
The definitive agreement to acquire BioLife, a cell therapy workflow solutions provider, adds a differentiated platform with deep end-market penetration. BioLife’s biopreservation media supports 18 commercial therapies, and the deal is expected to be accretive to growth, margin, and EPS, with at least $20 million in synergies in year one.
5. Integrated Solutions and APAC Expansion
Repligen is launching an integrated solutions team to cross-sell its full A-to-Z portfolio, focusing initially on ADCs and new modalities, with a special emphasis on APAC and China. China’s clinical trial leadership and rapid cell therapy adoption are key tailwinds, and local manufacturing partnerships are set to drive further regional gains.
Key Considerations
Q2 marks a turning point for Repligen as it leverages innovation and disciplined execution to offset legacy headwinds and position for multi-year growth. Investors should track the durability of protein and analytics outperformance, the pace of filtration normalization, and integration of BioLife post-close.
Key Considerations:
- Portfolio Mix Shift: Protein and analytics are driving growth, while filtration and capital equipment are expected to rebound in 2027, setting up a more diversified revenue base.
- Margin Expansion Trajectory: Continued operating leverage and cost discipline, even as second-half investments ramp, support a credible path to long-term margin targets.
- BioLife Integration and Cell Therapy Exposure: The BioLife deal accelerates Repligen’s move into cell therapy, with synergies and cross-selling opportunities central to the growth narrative.
- APAC and China as Growth Engines: Regional momentum is expected to continue, with local manufacturing and clinical trial activity supporting sustained demand.
Risks
Repligen’s near-term risks include continued softness in filtration and capital equipment, which could persist if customer inventory or site readiness delays extend beyond Q3. Integration risk around BioLife, competitive pressures in high-growth APAC markets, and potential tariff or regulatory volatility could also impact results. Management’s guidance assumes no further macro shocks or significant shifts in biopharma funding trends.
Forward Outlook
For Q3 2026, Repligen guided to:
- Slight sequential revenue increase from Q2
- Adjusted gross margin expected to be the lowest of the year, with improvement in Q4 driven by volume leverage
For full-year 2026, management raised guidance:
- Organic revenue growth of 10.5% to 13.5%
- Adjusted operating margin of 15.7% to 16%
- Adjusted EPS of $2.03 to $2.09
Management cited robust order momentum, protein and analytics outperformance, and a strong APAC pipeline as drivers of increased confidence.
- Filtration normalization expected by Q4
- BioLife not yet included in guidance, pending Q4 close
Takeaways
Repligen’s Q2 results demonstrate the power of portfolio repositioning, operational discipline, and strategic M&A to drive sustainable growth and margin expansion.
- Protein and Analytics Outperformance: These segments are now the company’s primary growth engines, offsetting temporary filtration weakness and enabling above-market growth.
- Margin Expansion and Guidance Raise: Strong cost controls and favorable product mix are delivering operating leverage and underpin the full-year guidance increase.
- 2027 Setup and BioLife Integration: Backlog build in equipment, APAC momentum, and the BioLife acquisition position Repligen for a multi-year growth cycle as market headwinds abate.
Conclusion
Repligen’s Q2 marks a clear inflection point, with innovation-led growth and disciplined execution driving both top-line and margin outperformance. The BioLife acquisition and integrated solutions strategy signal a bold pivot into higher-growth modalities, setting the stage for sustained, diversified expansion.
Industry Read-Through
Repligen’s results highlight a broader industry pivot toward recurring revenue, integrated solutions, and exposure to cell and gene therapy workflows. Bioprocessing peers facing filtration or equipment headwinds may see similar near-term softness, but the order momentum and backlog build suggest a 2027 rebound is likely sector-wide. APAC and China are emerging as critical growth drivers, with local partnerships and clinical trial activity reshaping competitive dynamics. Strategic M&A and lifecycle management will be key differentiators as the sector shifts from legacy capex cycles to innovation-driven, recurring models.